Literature DB >> 7101234

Inhibition of platelet function of antiarrhythmic drugs, verapamil and disopyramide.

P Han, C Boatwright, N G Ardlie.   

Abstract

Various cardiovascular drugs such as nitrates and propranolol, used in the treatment of coronary artery disease have been shown to have an antiplatelet effect. We have studied the in vitro effects of two antiarrhythmic drugs, verapamil and disopyramide, and have shown their inhibitory effect on platelet function. Verapamil, a calcium channel blocker, inhibited the second phase of platelet aggregation induced by adenosine diphosphate (*ADP) and inhibited aggregation induced by collagen. Disopyramide similarly inhibited the second phase of platelet aggregation caused by ADP and aggregation induced by collagen. Either drug in synergism with propranolol inhibited ADP or collagen-induced platelet aggregation. Disopyramide at high concentrations inhibited arachidonic acid whereas verapamil was without effect. Verapamil, but not disopyramide, inhibited aggregated induced by the ionophore A23187.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7101234

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Antiplatelet effects of oral diltiazem, propranolol, and their combination.

Authors:  M E Ring; J J Corrigan; P E Fenster
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

2.  The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.

Authors:  J L Francis; O S Roath; V F Challenor; D G Waller
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

Review 3.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.